WO2008105260A1 - Agent thérapeutique permettant d'améliorer le pronostic après l'amputation d'un membre inférieur - Google Patents
Agent thérapeutique permettant d'améliorer le pronostic après l'amputation d'un membre inférieur Download PDFInfo
- Publication number
- WO2008105260A1 WO2008105260A1 PCT/JP2008/052694 JP2008052694W WO2008105260A1 WO 2008105260 A1 WO2008105260 A1 WO 2008105260A1 JP 2008052694 W JP2008052694 W JP 2008052694W WO 2008105260 A1 WO2008105260 A1 WO 2008105260A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- ameliorating
- prognosis
- lower limb
- limb amputation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 238000011542 limb amputation Methods 0.000 title abstract 2
- 210000003141 lower extremity Anatomy 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 238000001356 surgical procedure Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract 1
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un agent thérapeutique permettant d'améliorer le pronostic après l'amputation d'un membre inférieur par suite d'une maladie artérielle périphérique grave. L'agent thérapeutique comprend un dérivé de la prostaglandine E1 (PGE1) représenté par la formule (I) (AS-013) comme principe actif. De préférence, l'agent thérapeutique revêt la forme posologique d'une préparation pour administration intraveineuse ou locale. De façon davantage préférée, la préparation pour injection revêt la forme posologique d'une préparation liposomale dont l'ingrédient actif AS-013 est incorporé dans une particule lipidique.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008800063978A CN101622003B (zh) | 2007-02-28 | 2008-02-19 | 改善下肢截肢手术的预后的治疗剂 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-049363 | 2007-02-28 | ||
| JP2007049363 | 2007-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008105260A1 true WO2008105260A1 (fr) | 2008-09-04 |
Family
ID=39721096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/052694 WO2008105260A1 (fr) | 2007-02-28 | 2008-02-19 | Agent thérapeutique permettant d'améliorer le pronostic après l'amputation d'un membre inférieur |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101622003B (fr) |
| WO (1) | WO2008105260A1 (fr) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710833A (ja) * | 1991-04-16 | 1995-01-13 | Yutaka Mizushima | プロスタグランジン類縁体、その脂肪乳剤およびその用途 |
| WO1999009992A1 (fr) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Promoteurs de neovascularisation |
| WO1999011268A1 (fr) * | 1997-08-28 | 1999-03-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Agents promoteurs et agents potentialisateurs de la neovascularisation |
-
2008
- 2008-02-19 CN CN2008800063978A patent/CN101622003B/zh active Active
- 2008-02-19 WO PCT/JP2008/052694 patent/WO2008105260A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710833A (ja) * | 1991-04-16 | 1995-01-13 | Yutaka Mizushima | プロスタグランジン類縁体、その脂肪乳剤およびその用途 |
| WO1999009992A1 (fr) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Promoteurs de neovascularisation |
| WO1999011268A1 (fr) * | 1997-08-28 | 1999-03-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Agents promoteurs et agents potentialisateurs de la neovascularisation |
Non-Patent Citations (1)
| Title |
|---|
| ITO M.: "Heisokusei Domyaku Kokasho -Gainen.Bunrui.Shindan.Chiryo-", SHINJIDAI NO TONYOBYOGAKU (4) - BYOIN.SHINDAN.CHIRYO KENKYU NO SHINPO-, KABUSHIKI KASIHA NIPPON RINSHOSHA, 28 October 2002 (2002-10-28), pages 334 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101622003A (zh) | 2010-01-06 |
| CN101622003B (zh) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| WO2007017135A3 (fr) | Procede de preparation d'olmesartane medoxomil | |
| WO2008027557A3 (fr) | Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité | |
| EP1834637A4 (fr) | Preparation prophylactique/therapeutique contre une maladie due aux radicaux libres | |
| WO2008069941A3 (fr) | Forme pharmaceutique d'ibuprofène à libération modifiée | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| WO2012021107A3 (fr) | Formulation de liposomes pour l'administration d'un médicament dans l'œil | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| UA96575C2 (en) | Process for the preparation of olmesartan medoxomil | |
| WO2009028605A1 (fr) | Agent destiné à la prophylaxie ou au soulagement d'un trouble nerveux périphérique induit par un agent anti-cancéreux | |
| BR0210293A (pt) | Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral | |
| WO2012012305A3 (fr) | Polythérapie à l'aide d'un complexe de ruthénium | |
| WO2008008701A3 (fr) | Composés thérapeutiques | |
| WO2010075315A3 (fr) | Formules topiques d'inhibiteurs de flap pouvant être appliquées sur un oeil | |
| WO2007145863A3 (fr) | Formulation à libération prolongée de naltréxone | |
| WO2008008882A3 (fr) | Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation | |
| WO2008133297A1 (fr) | Agent thérapeutique ou prophylactique de la dyskinésie | |
| WO2007133796A3 (fr) | Procédés et compositions de traitement de l'apnée du sommeil | |
| WO2011049979A3 (fr) | Formulations injectables pour administration intra-articulaire ou péri-articulaire | |
| PH12013500711A1 (en) | Acylbenzene derivative | |
| WO2008099781A1 (fr) | Agent thérapeutique ou prophylactique pour une maladie démyélinisante comprenant un dérivé d'amino alcool comme ingrédient actif | |
| WO2008105260A1 (fr) | Agent thérapeutique permettant d'améliorer le pronostic après l'amputation d'un membre inférieur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880006397.8 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08711518 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08711518 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |